Yang Hong, Deng Liwei, Li Tingting, Shen Xue, Yan Jie, Zuo Liangming, Wu Chunhui, Liu Yiyao
J Biomed Nanotechnol. 2015 Dec;11(12):2124-36. doi: 10.1166/jbn.2015.2168.
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. One of the effective approaches to overcome MDR is to use nanoparticle-mediated the gene silence of chemotherapeutic export proteins by RNA interference to increase drug accumulation in drug resistant cancer cells. In this work, a new co-delivery system, DOX-PLGA/PEI/P-gp shRNA nanobubbles (NBs) around 327 nm, to overcome doxorubicin (DOX) resistance in MCF-7 human breast cancer was designed and developed. Positively charged polyethylenimine (PEI) were modified onto the surface of DOX-PLGA NBs through DCC/NHS crosslinking, and could efficiently condense P-gp shRNA into DOX-PLGA/PEI NBs at vector/shRNA weight ratios of 70:1 and above. An in vitro release profile demonstrated an efficient DOX release (more than 80%) from DOX-PLGA/PEI NBs at pH 4.4, suggesting a pH-responsive drug release for the multifunctionalized NBs. Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). The IC50 of DOX-PLGA NBs against MCF-7/ADR cells was 2-fold lower than that of free DOX. The increased cellular uptake and nuclear accumulation of DOX delivered by DOX-PLGA/PEI/P-gp shRNA NBs in MCF-7/ADR cells was confirmed by fluorescence microscopy and fluorescence spectrophotometry, and might be owning to the down-regulation of P-gp and reduced the efflux of DOX. The cellular uptake mechanism of DOX-PLGA/PEI/P-gp shRNA NBs indicated that the macropinocytosis was one of the pathways for the uptake of NBs by MCF-7/ADR cells, which was also an energy-dependent process. Furthermore, the in vitro cellular ultrasound imaging suggested that the employment of the DOX-PLGA/PEI/P-gp shRNA NBs could efficiently enhance ultrasound imaging of cancer cells. These results demonstrated that the developed DOX-PLGA/PEI/P-gp shRNA NBs is a potential, safe and efficient theranotic agent for cancer therapy and diagnostics.
多药耐药性(MDR)是癌症化疗成功的主要障碍。克服MDR的有效方法之一是使用纳米颗粒介导RNA干扰使化疗药物外排蛋白的基因沉默,以增加耐药癌细胞中的药物积累。在这项工作中,设计并开发了一种新的共递送系统,即粒径约为327 nm的阿霉素-聚乳酸-羟基乙酸共聚物/聚乙烯亚胺/P-糖蛋白短发夹RNA纳米泡(NBs),以克服MCF-7人乳腺癌中的阿霉素(DOX)耐药性。通过二环己基碳二亚胺/ N-羟基琥珀酰亚胺交联将带正电荷的聚乙烯亚胺(PEI)修饰到DOX-PLGA NBs的表面,并且在载体/ shRNA重量比为70:1及以上时能够有效地将P-糖蛋白shRNA浓缩到DOX-PLGA/PEI NBs中。体外释放曲线表明,DOX-PLGA/PEI NBs在pH 4.4时能有效释放DOX(超过80%),表明多功能化NBs具有pH响应性药物释放特性。细胞实验结果进一步表明,DOX-PLGA/PEI/P-糖蛋白shRNA NBs可以促进DOX进入细胞,并增强DOX对MCF-7/ADR细胞(一种DOX耐药且P-糖蛋白(P-gp)过表达的癌细胞系)的细胞增殖抑制作用。DOX-PLGA NBs对MCF-7/ADR细胞的半数抑制浓度(IC50)比游离DOX低2倍。荧光显微镜和荧光分光光度法证实,DOX-PLGA/PEI/P-糖蛋白shRNA NBs递送的DOX在MCF-7/ADR细胞中的细胞摄取和核积累增加,这可能归因于P-糖蛋白的下调和DOX外排的减少。DOX-PLGA/PEI/P-糖蛋白shRNA NBs的细胞摄取机制表明,巨胞饮作用是MCF-7/ADR细胞摄取NBs的途径之一,这也是一个能量依赖过程。此外,体外细胞超声成像表明,使用DOX-PLGA/PEI/P-糖蛋白shRNA NBs可以有效增强癌细胞的超声成像。这些结果表明,所开发的DOX-PLGA/PEI/P-糖蛋白shRNA NBs是一种用于癌症治疗和诊断的潜在、安全且高效的诊疗试剂。